
AXIM Begins Clinical Trials with CBG Ointment
The Phase I trials will examine AX-1602’s clinical efficacy for the treatment of psoriasis and eczema.
AXIM Biotechnologies, a Netherlands-based biotechnology company, announced that it would be entering clinical trials with its patent-pending cannabigerol (CBG) topical ointment formulation AX-1602, the company said in a May 16, 2016 press statement to BioPharm International. AX-1602’s indications for the Phase I trials include psoriasis and eczema (atopic dermatitis). Marcus Meinardi, PhD, MD, a dermatologist and specialist on psoriasis and atopic dermatitis, will be leading the trials, which will take place at The Maurits Clinics in The Hague.
CBG is a non-psychoactive cannabinoid found in the plant genus Cannabis. Previous research has indicated that cannabinoids, such as CBG, may have therapeutic value in the treatment of skin conditions. Among other clinical uses, CBG can be used by patients to reduce muscle spasm and pain, and contains anti-inflammatory properties,
In a statement, Lekhram Changoer, chief technology officer of AXIM said, “AX-1602 ointment will be tested with different concentrations of cannabinoids and will be placebo controlled. Following the successful completion of this clinical trial, AXIM products will be registered as an ointment for various skin disorders.” AXIM also has
Other companies have also been testing the efficacy of cannabinoids for the treatment of various diseases. GW Pharmaceuticals, a London-based biopharmaceutical company,
Source: AXIM Biotechnologies
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.